Joint Action on Rare Cancers

The European Society for Paediatric Oncology (SIOP) statement:

​

"90% of newly diagnosed paediatric cancer patients are treated within EU prospective clinical trials or according to European recommendations established through clinical research. Phase 3 protocols are used for the majority of the paediatric cancer population. The paediatric cancer community is well informed of the ongoing trials and guidelines through the respective European Clinical Trial Groups and SIOP Europe".

​

Relevant documents include:

 

The European Standards of Care for Children with Cancer (SIOP Europe, 2009): https://www.siope.eu/wp-content/uploads/2013/09/European_Standards_final_2011.pdf 

​

Recommendations for the Organisation of Care in Paediatric Radiation Oncology across Europe (Janssens GO, 2019): 

https://www.ejcancer.com/article/S0959-8049(19)30182-0/fulltext

​

ESMO guidelines incl. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (Casali et al., 2018): https://www.esmo.org/Guidelines/Sarcoma-and-GIST/Bone-Sarcomas

​

PanCare Guidelines on Survivorship (PanCare/IGHG): https://www.pancare.eu/en/guidelines

​

The work on very rare tumour guidelines in the European Cooperative Study Group for Pediatric Rare Tumors: https://www.raretumors-children.eu

​

 ESGO – SIOP Europe Guideline on Non-Epithelial Ovarian Cancers in Adolescents and Young Adults (under development)

​